NYSE:RCUS

Arcus Biosciences Competitors

$30.49
-0.81 (-2.59 %)
(As of 04/12/2021 05:11 PM ET)
Add
Compare
Today's Range
$29.18
Now: $30.49
$31.34
50-Day Range
$28.06
MA: $33.45
$39.01
52-Week Range
$15.03
Now: $30.49
$42.36
Volume554,017 shs
Average Volume539,090 shs
Market Capitalization$2.16 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.26

Competitors

Arcus Biosciences (NYSE:RCUS) Vs. UTHR, MRTX, BBIO, GWPH, RARE, and ASND

Should you be buying RCUS stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Arcus Biosciences, including United Therapeutics (UTHR), Mirati Therapeutics (MRTX), BridgeBio Pharma (BBIO), GW Pharmaceuticals (GWPH), Ultragenyx Pharmaceutical (RARE), and Ascendis Pharma A/S (ASND).

United Therapeutics (NASDAQ:UTHR) and Arcus Biosciences (NYSE:RCUS) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Profitability

This table compares United Therapeutics and Arcus Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
United Therapeutics33.25%15.48%11.31%
Arcus Biosciences-112.63%-27.43%-20.96%

Institutional and Insider Ownership

90.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 60.6% of Arcus Biosciences shares are owned by institutional investors. 10.9% of United Therapeutics shares are owned by company insiders. Comparatively, 19.7% of Arcus Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares United Therapeutics and Arcus Biosciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
United Therapeutics$1.45 billion6.11$-104,500,000.00($2.39)-83.09
Arcus Biosciences$15 million144.07$-84,710,000.00($1.93)-15.80

Arcus Biosciences has lower revenue, but higher earnings than United Therapeutics. United Therapeutics is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for United Therapeutics and Arcus Biosciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
United Therapeutics00703.00
Arcus Biosciences00903.00

United Therapeutics presently has a consensus target price of $219.5714, suggesting a potential upside of 10.57%. Arcus Biosciences has a consensus target price of $49.9091, suggesting a potential upside of 63.69%. Given Arcus Biosciences' higher possible upside, analysts plainly believe Arcus Biosciences is more favorable than United Therapeutics.

Risk & Volatility

United Therapeutics has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500.

Summary

Arcus Biosciences beats United Therapeutics on 7 of the 13 factors compared between the two stocks.

Mirati Therapeutics (NASDAQ:MRTX) and Arcus Biosciences (NYSE:RCUS) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Profitability

This table compares Mirati Therapeutics and Arcus Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mirati TherapeuticsN/A-60.01%-54.21%
Arcus Biosciences-112.63%-27.43%-20.96%

Institutional and Insider Ownership

94.9% of Mirati Therapeutics shares are owned by institutional investors. Comparatively, 60.6% of Arcus Biosciences shares are owned by institutional investors. 4.1% of Mirati Therapeutics shares are owned by company insiders. Comparatively, 19.7% of Arcus Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Mirati Therapeutics and Arcus Biosciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mirati Therapeutics$3.34 million2,420.73$-213,260,000.00($5.69)-28.06
Arcus Biosciences$15 million144.07$-84,710,000.00($1.93)-15.80

Arcus Biosciences has higher revenue and earnings than Mirati Therapeutics. Mirati Therapeutics is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Mirati Therapeutics and Arcus Biosciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mirati Therapeutics151002.56
Arcus Biosciences00903.00

Mirati Therapeutics presently has a consensus target price of $218.5714, suggesting a potential upside of 36.88%. Arcus Biosciences has a consensus target price of $49.9091, suggesting a potential upside of 63.69%. Given Arcus Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Arcus Biosciences is more favorable than Mirati Therapeutics.

Risk & Volatility

Mirati Therapeutics has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500.

Summary

Arcus Biosciences beats Mirati Therapeutics on 9 of the 14 factors compared between the two stocks.

Arcus Biosciences (NYSE:RCUS) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Arcus Biosciences and BridgeBio Pharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arcus Biosciences00903.00
BridgeBio Pharma01902.90

Arcus Biosciences presently has a consensus price target of $49.9091, suggesting a potential upside of 63.69%. BridgeBio Pharma has a consensus price target of $72.8889, suggesting a potential upside of 35.08%. Given Arcus Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Arcus Biosciences is more favorable than BridgeBio Pharma.

Profitability

This table compares Arcus Biosciences and BridgeBio Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arcus Biosciences-112.63%-27.43%-20.96%
BridgeBio PharmaN/A-109.88%-48.54%

Valuation & Earnings

This table compares Arcus Biosciences and BridgeBio Pharma's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcus Biosciences$15 million144.07$-84,710,000.00($1.93)-15.80
BridgeBio Pharma$40.56 million198.17$-260,590,000.00($2.48)-21.76

Arcus Biosciences has higher earnings, but lower revenue than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

60.6% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 95.5% of BridgeBio Pharma shares are owned by institutional investors. 19.7% of Arcus Biosciences shares are owned by company insiders. Comparatively, 40.3% of BridgeBio Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Arcus Biosciences has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500.

Summary

Arcus Biosciences beats BridgeBio Pharma on 7 of the 13 factors compared between the two stocks.

Arcus Biosciences (NYSE:RCUS) and GW Pharmaceuticals (NASDAQ:GWPH) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Arcus Biosciences and GW Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arcus Biosciences00903.00
GW Pharmaceuticals010402.29

Arcus Biosciences presently has a consensus price target of $49.9091, suggesting a potential upside of 63.69%. GW Pharmaceuticals has a consensus price target of $204.0909, suggesting a potential downside of 6.28%. Given Arcus Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Arcus Biosciences is more favorable than GW Pharmaceuticals.

Profitability

This table compares Arcus Biosciences and GW Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arcus Biosciences-112.63%-27.43%-20.96%
GW Pharmaceuticals-11.05%-7.46%-6.13%

Valuation & Earnings

This table compares Arcus Biosciences and GW Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcus Biosciences$15 million144.07$-84,710,000.00($1.93)-15.80
GW Pharmaceuticals$311.33 million21.93$-9,020,000.00($0.24)-907.38

GW Pharmaceuticals has higher revenue and earnings than Arcus Biosciences. GW Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

60.6% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 81.0% of GW Pharmaceuticals shares are owned by institutional investors. 19.7% of Arcus Biosciences shares are owned by company insiders. Comparatively, 3.1% of GW Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Arcus Biosciences has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, GW Pharmaceuticals has a beta of 2.15, indicating that its stock price is 115% more volatile than the S&P 500.

Summary

GW Pharmaceuticals beats Arcus Biosciences on 8 of the 14 factors compared between the two stocks.

Arcus Biosciences (NYSE:RCUS) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Arcus Biosciences and Ultragenyx Pharmaceutical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arcus Biosciences00903.00
Ultragenyx Pharmaceutical06802.57

Arcus Biosciences presently has a consensus price target of $49.9091, suggesting a potential upside of 63.69%. Ultragenyx Pharmaceutical has a consensus price target of $131.20, suggesting a potential upside of 30.51%. Given Arcus Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Arcus Biosciences is more favorable than Ultragenyx Pharmaceutical.

Profitability

This table compares Arcus Biosciences and Ultragenyx Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arcus Biosciences-112.63%-27.43%-20.96%
Ultragenyx Pharmaceutical-119.19%-50.69%-26.87%

Valuation & Earnings

This table compares Arcus Biosciences and Ultragenyx Pharmaceutical's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcus Biosciences$15 million144.07$-84,710,000.00($1.93)-15.80
Ultragenyx Pharmaceutical$103.71 million64.90$-402,730,000.00($7.36)-13.66

Arcus Biosciences has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Arcus Biosciences is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

60.6% of Arcus Biosciences shares are owned by institutional investors. 19.7% of Arcus Biosciences shares are owned by company insiders. Comparatively, 8.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Arcus Biosciences has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 2.19, indicating that its stock price is 119% more volatile than the S&P 500.

Summary

Arcus Biosciences beats Ultragenyx Pharmaceutical on 12 of the 14 factors compared between the two stocks.

Arcus Biosciences (NYSE:RCUS) and Ascendis Pharma A/S (NASDAQ:ASND) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Profitability

This table compares Arcus Biosciences and Ascendis Pharma A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arcus Biosciences-112.63%-27.43%-20.96%
Ascendis Pharma A/S-4,042.79%-55.72%-49.42%

Volatility & Risk

Arcus Biosciences has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Arcus Biosciences and Ascendis Pharma A/S, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arcus Biosciences00903.00
Ascendis Pharma A/S011102.92

Arcus Biosciences presently has a consensus price target of $49.9091, suggesting a potential upside of 63.69%. Ascendis Pharma A/S has a consensus price target of $187.6667, suggesting a potential upside of 52.12%. Given Arcus Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Arcus Biosciences is more favorable than Ascendis Pharma A/S.

Institutional & Insider Ownership

60.6% of Arcus Biosciences shares are owned by institutional investors. 19.7% of Arcus Biosciences shares are owned by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Arcus Biosciences and Ascendis Pharma A/S's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcus Biosciences$15 million144.07$-84,710,000.00($1.93)-15.80
Ascendis Pharma A/S$14.98 million442.67$-244,180,000.00($5.25)-23.50

Arcus Biosciences has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Arcus Biosciences beats Ascendis Pharma A/S on 10 of the 14 factors compared between the two stocks.


Arcus Biosciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
United Therapeutics logo
UTHR
United Therapeutics
1.7$198.59-2.4%$8.85 billion$1.45 billion18.79Analyst Revision
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$159.68-6.6%$8.09 billion$3.34 million-20.74
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$53.96-1.0%$8.04 billion$40.56 million-15.82Analyst Report
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$217.77-0.1%$6.83 billion$311.33 million-126.61
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.6$100.53-2.9%$6.73 billion$103.71 million-22.90
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$123.37-1.8%$6.63 billion$14.98 million-15.03High Trading Volume
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$62.78-1.0%$6.52 billion$87.99 million-74.74News Coverage
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$43.90-2.0%$6.17 billion$150,000.00-20.71
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$40.87-3.6%$5.76 billion$1.12 billion85.15
Allakos logo
ALLK
Allakos
1.7$104.41-0.6%$5.55 billionN/A-38.11
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$69.38-1.7%$5.51 billion$380.83 million-8.87News Coverage
Perrigo logo
PRGO
Perrigo
2.5$40.52-0.0%$5.41 billion$4.84 billion-675.22
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$92.61-1.7%$5.37 billion$66.51 million17.09
Schrödinger logo
SDGR
Schrödinger
1.5$73.88-0.0%$5.17 billion$85.54 million0.00Insider Selling
Galapagos logo
GLPG
Galapagos
1.3$77.39-0.5%$5.07 billion$1.00 billion-11.73Analyst Report
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$55.31-2.2%$4.58 billionN/A0.00
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$70.77-1.9%$4.39 billionN/A-5.77Analyst Revision
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$74.68-2.6%$4.36 billion$6.87 million-7.22Analyst Report
Analyst Revision
News Coverage
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.30-0.2%$4.26 billion$204.89 million-36.63
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$75.86-2.0%$4.04 billion$1.11 billion24.39
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$64.76-2.4%$3.91 billion$806.43 million-9.17Unusual Options Activity
LEGN
Legend Biotech
1.2$27.81-2.3%$3.67 billion$64.39 million0.00
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$74.94-5.4%$3.67 billionN/A-21.35High Trading Volume
News Coverage
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$52.24-1.0%$3.64 billion$117.91 million-10.60
I-Mab logo
IMAB
I-Mab
1.4$47.86-7.9%$3.44 billion$4.31 million-1.66
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.68-0.3%$3.41 billion$114.62 million-7.53Analyst Revision
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$41.59-0.1%$3.34 billionN/A-5.61
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.13-1.0%$3.31 billion$306.98 million-6.74
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$20.43-0.2%$3.27 billion$339.08 million-11.88
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.31-6.7%$3.23 billion$36.13 million-69.12Unusual Options Activity
News Coverage
Insmed logo
INSM
Insmed
1.2$30.82-2.9%$3.18 billion$136.47 million-11.85
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$85.87-3.0%$3.11 billion$26.52 million-7.57
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$112.62-3.8%$3.04 billionN/A-56.03
Alkermes logo
ALKS
Alkermes
1.4$18.78-1.3%$2.99 billion$1.17 billion-40.83Unusual Options Activity
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$67.95-0.4%$2.98 billion$421.03 million23.93Analyst Report
Analyst Revision
Arvinas logo
ARVN
Arvinas
1.5$60.45-5.0%$2.95 billion$42.98 million-23.61
Organogenesis logo
ORGO
Organogenesis
1.0$22.98-0.6%$2.94 billion$260.98 million-383.00Gap Down
MorphoSys logo
MOR
MorphoSys
0.3$22.17-0.9%$2.92 billion$80.43 million105.58
Viela Bio logo
VIE
Viela Bio
0.8$53.01-0.0%$2.91 billion$50 million-7.55
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.59-0.3%$2.78 billion$644.77 million-10.36
OPKO Health logo
OPK
OPKO Health
1.9$4.06-3.0%$2.72 billion$901.90 million-22.55
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.43-1.1%$2.63 billion$306.49 million25.20
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.71-0.1%$2.57 billion$60,000.00-9.85News Coverage
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$44.05-0.5%$2.54 billion$25 million-8.81
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$40.97-3.8%$2.53 billionN/A-22.51
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$39.97-2.0%$2.48 billion$2.11 million-8.65
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.29-1.1%$2.46 billion$182.24 million-8.08
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$144.90-5.9%$2.41 billion$120.28 million-146.36
Cryoport logo
CYRX
Cryoport
1.9$51.64-1.3%$2.36 billion$33.94 million-89.03Insider Selling
ALX Oncology logo
ALXO
ALX Oncology
1.9$57.95-10.0%$2.33 billionN/A0.00
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.